Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

49.58 -1.08 (-2.13%)
Streaming Delayed Price Updated: 1:22 PM EST, Nov 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
39 40 Next >
News headline image
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant ↗
Read the latest report on NanoViricides here 
Via Benzinga
News headline image
Stock Split Watch: Is Regeneron Pharmaceuticals Next? ↗
If the biotech does split its stock, it will be a first for the company. 
Via The Motley Fool
News headline image
Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst ↗
Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Therapeutics. 
Via Benzinga
News headline image
Apple Defends Its $19B Google Search Deal, Hollywood's Writers Secure Credit For AI Training, China's Ambitious Chip Fund Faces Headwinds: Today's Top Stories ↗
Benzinga Alibaba's Logistics Arm Cainiao Files For Hong Kong IPO 
Via Benzinga
Topics Artificial Intelligence
News headline image
Looking Into Sanofi's Recent Short Interest ↗
 
Via Benzinga
News headline image
(SNY) - Analyzing Sanofi's Short Interest ↗
 
Via Benzinga
News headline image
Weight Loss Drugs Like Wegovy Could Have Linked Anesthesia Complications, European Medicines Agency To Investigate ↗
The European Medicines Agency (EMA) is set to address concerns related to patients taking drugs such as Novo Nordisk A/S's (NYSE 
Via Benzinga
News headline image
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant ↗
Read the latest report on NanoViricides here 
Via Benzinga
News headline image
Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
CDC Backs Pfizer's RSV Infection Maternal Vaccine During Pregnancy As Protection For Infants ↗
Friday, The Centers for Disease Control and Prevention recommended the first respiratory syncytial virus (RSV) vaccine for pregnant people to protect their newborns from severe RSV 
Via Benzinga
News headline image
2 Top Biotech Stocks to Buy Right Now ↗
These drugmakers are among the most dominant in the world. 
Via The Motley Fool
News headline image
Why Shares of MacroGenics Are Jumping Thursday ↗
The company announced second-quarter earnings. 
Via The Motley Fool
News headline image
Dow Tumbles 200 Points; Darden Restaurants Posts Upbeat Profit ↗
U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 200 points on Thursday. The Dow traded down 0.58% to 34,239.48 while the NASDAQ fell 1.20% to 13,307.77. The S&P... 
Via Benzinga
Topics Stocks
News headline image
Why Seelos Therapeutics Shares Are Trading Lower By 31%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares climbed 81.5% to $0.2793 after jumping 64% on Wednesday. 
Via Benzinga
News headline image
Gold Down Over 1%; FedEx Shares Rise On Earnings Beat ↗
U.S. stocks traded lower midway through trading, with the Dow Jones falling around 150 points on Thursday. The Dow traded down 0.46% to 34,284.15 while the NASDAQ fell 1.05% to 13,327.80. The S&P 500... 
Via Benzinga
Topics Stocks
News headline image
Nasdaq Down Over 1%; US Initial Jobless Claims Fall More Than Expected ↗
U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 150 points on Thursday. Following the market opening Thursday, the Dow traded down 0.56% to 34,248.45 while the NASDAQ fell... 
Via Benzinga
Topics Stocks
News headline image
Why Is Kidney-Disease Focused Travere Therapeutics Stock Trading Lower Today? ↗
Travere Therapeutics Inc (NASDAQ: TVTX) announced 
Via Benzinga
News headline image
Elon Musk-Backed Neuralink Starts Participant Enrollment For Paralysis, Eli Lilly Cracks Down on Counterfeit Weight Loss Drugs, Meta Looks to Capitalize on India's In-App Payment Surge: Today's Top Stories ↗
Benzinga 
Via Benzinga
News headline image
FDA Rejects EpiPen Alternative - ARS Pharmaceuticals' Allergic Reaction Nasal Spray ↗
The FDA issued a Complete Response Letter regarding ARS Pharmaceuticals Inc's (NASDAQ: SPRY) New Drug Application (NDA) for neffy (epinephrine nasal spray) in the treatment of Allergic Reactions (Type... 
Via Benzinga
News headline image
3 Stocks to Buy to Ride Europe’s Coming Market Surge ↗
With Europe’s markets looking to perform better in the second half of 2023, here are three European stocks to buy to ride the wave. 
Via InvestorPlace
News headline image
Moderna's R&D Day Unveils Strategic Roadmap Beyond COVID Franchise: Goldman Sachs ↗
On Wednesday, Moderna Inc (NASDAQ: MRNA) conducted an R&D Day event outlining its strategic initiatives across four key areas - Respiratory Vaccines, Latent/Other Vaccines, Oncology Therapeutics,  
Via Benzinga
News headline image
This Market Could Be Worth $10 Billion by 2030 -- 2 Stocks to Buy Now ↗
This market is currently in its infancy. 
Via The Motley Fool
News headline image
'Transformative Event' For First Wave BioPharma: License Agreement for Hopeful Gastrointestinal Candidate From Sanofi ↗
First Wave BioPharma Inc (NASDAQ: FWBI) announced an agreement with Sanofi SA (NASDAQ: SNY) to license Capeserod, a selective 5-HT4 receptor partial agonist, which First Wave will repurpose and develop... 
Via Benzinga
News headline image
Flu Vaccine Results Give Moderna (MRNA) Stock a Shot in the Arm ↗
Moderna released encouraging results for its late-stage trial of its flu vaccine. Now, MRNA stock is looking like more than a one-trick pony. 
Via InvestorPlace
News headline image
Moderna Stock Has Been Beaten Up; Why The CFO Says Its Story Is 'Misunderstood' ↗
Moderna unveiled promising results in flu on Wednesday, adding to its respiratory suite. 
Via Investor's Business Daily
News headline image
Could This Medicine Be the Next Winner for Novartis? ↗
The Swiss drugmaker recently reported that a drug candidate met the primary endpoints in phase 3 clinical trials. 
Via The Motley Fool
News headline image
FDA Greenlights Pfizer's RSV Vaccine: Moms Can Now Protect Babies Before Birth ↗
Monday, the FDA approved Pfizer Inc's (NYSE: PFE) Abrysvo (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, to prevent the infection in infants from birth... 
Via Benzinga
News headline image
Is Regeneron Pharmaceuticals Still a Top Growth Stock? ↗
The biotech's focus on innovation could be a boon for shareholders. 
Via The Motley Fool
News headline image
2 Biotech Stocks That Could Make You Richer ↗
Neither is performing particularly well this year compared to the broader market, but don't let that chase you away. 
Via The Motley Fool
News headline image
Amazon's Boon for Diabetes Patients - Streamlining Pharmacy Discounts ↗
Amazon.Com Inc's (NASDAQ: AMZN) online pharmacy launched a new initiativ 
Via Benzinga
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
39 40 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.